<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated">
      <PMID Version="1">32920843</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>03</Month>
        <Day>04</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>03</Month>
        <Day>04</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1879-3479</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>152</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Mar</Month>
            </PubDate>
          </JournalIssue>
          <Title>International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics</Title>
          <ISOAbbreviation>Int J Gynaecol Obstet</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Letrozole versus clomiphene citrate for ovulation induction in anovulatory women with polycystic ovarian syndrome: A randomized controlled trial.</ArticleTitle>
        <Pagination>
          <StartPage>345</StartPage>
          <EndPage>350</EndPage>
          <MedlinePgn>345-350</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1002/ijgo.13375</ELocationID>
        <Abstract>
          <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To compare the efficacy of letrozole and clomiphene citrate (CC) for ovulation induction in infertile women with polycystic ovarian syndrome (PCOS).</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">In this assessor blind, randomized controlled trial, 90 infertile women with PCOS were randomized to receive either letrozole or CC for ovulation induction in incremental doses for a maximum of three cycles. Main outcome measures studied were endometrial thickness, ovulation rate, pregnancy rate, rate of monofollicular development, and time to conception.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">Mean endometrial thicknesses were 9.86 ± 2.32 mm and 9.39 ± 2.06 mm with letrozole and CC, respectively (P=0.751). Cumulative ovulation rates were 86.7% and 85.2% with letrozole and CC, respectively (P=0.751). Pregnancy was achieved in 42.2% of women in the letrozole group and 20.0% of women in the CC group (P=0.04). Monofollicular development was seen in 68.4% of ovulatory cycles in the letrozole group compared with 44.8% in the CC group (P=0.000). Mean time to achieve pregnancy was significantly shorter (log rank P=0.042) with letrozole (9.65 weeks) than with CC (11.07 weeks).</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Letrozole is a better alternative for ovulation induction in anovulatory women with PCOS as pregnancy rates are higher, time to pregnancy is shorter, and chances of multiple pregnancy are less because of high monofollicular growth.</AbstractText>
          <CopyrightInformation>© 2020 International Federation of Gynecology and Obstetrics.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Bansal</LastName>
            <ForeName>Shavina</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Obstetrics &amp; Gynecology, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Goyal</LastName>
            <ForeName>Manu</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Obstetrics &amp; Gynecology, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sharma</LastName>
            <ForeName>Charu</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Obstetrics &amp; Gynecology, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shekhar</LastName>
            <ForeName>Shashank</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Obstetrics &amp; Gynecology, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>14</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Int J Gynaecol Obstet</MedlineTA>
        <NlmUniqueID>0210174</NlmUniqueID>
        <ISSNLinking>0020-7292</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D005300">Fertility Agents, Female</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>1HRS458QU2</RegistryNumber>
          <NameOfSubstance UI="D002996">Clomiphene</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>7LKK855W8I</RegistryNumber>
          <NameOfSubstance UI="D000077289">Letrozole</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002996" MajorTopicYN="N">Clomiphene</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005300" MajorTopicYN="N">Fertility Agents, Female</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007247" MajorTopicYN="Y">Infertility, Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077289" MajorTopicYN="N">Letrozole</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010062" MajorTopicYN="Y">Ovulation Induction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011085" MajorTopicYN="Y">Polycystic Ovary Syndrome</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018873" MajorTopicYN="N">Pregnancy Rate</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Clomiphene citrate</Keyword>
        <Keyword MajorTopicYN="N">Infertility</Keyword>
        <Keyword MajorTopicYN="N">Letrozole</Keyword>
        <Keyword MajorTopicYN="N">Ovulation induction</Keyword>
        <Keyword MajorTopicYN="N">Polycystic ovarian syndrome</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>5</Month>
          <Day>5</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2020</Year>
          <Month>7</Month>
          <Day>25</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>9</Month>
          <Day>10</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>9</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>3</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>9</Month>
          <Day>13</Day>
          <Hour>20</Hour>
          <Minute>42</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">32920843</ArticleId>
        <ArticleId IdType="doi">10.1002/ijgo.13375</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Title>REFERENCES</Title>
        <Reference>
          <Citation>Practice Committee of the American Society for Reproductive Medicine. Definitions of infertility and recurrent pregnancy loss. Fertil Steril. 2008;90(5.Suppl):S60.</Citation>
        </Reference>
        <Reference>
          <Citation>Hoffman BL, Ed. Williams gynecology. 3rd edn. New York: McGraw-Hill Education; 2016:1270 p.</Citation>
        </Reference>
        <Reference>
          <Citation>Roy K, Baruah J, Singla S, et al. A prospective randomized trial comparing the efficacy of Letrozole and Clomiphene citrate in induction of ovulation in polycystic ovarian syndrome. J Hum Reprod Sci. 2012;5:20.</Citation>
        </Reference>
        <Reference>
          <Citation>Amer SA, Smith J, Mahran A, Fox P, Fakis A. Double-blind randomized controlled trial of letrozole versus clomiphene citrate in subfertile women with polycystic ovarian syndrome. Hum Reprod. 2017;32:1631-1638.</Citation>
        </Reference>
        <Reference>
          <Citation>Mitwally MFM, Casper RF. Use of an aromatase inhibitor for induction of ovulation in patients with an inadequate response to clomiphene citrate. Fertil Steril. 2001;75:305-309.</Citation>
        </Reference>
        <Reference>
          <Citation>Tulandi T, Martin J, Al-Fadhli R, et al. Congenital malformations among 911 newborns conceived after infertility treatment with letrozole or clomiphene citrate. Fertil Steril. 2006;85:1761-1765.</Citation>
        </Reference>
        <Reference>
          <Citation>Forman R, Gill S, Moretti M, Tulandi T, Koren G, Casper R. Fetal safety of letrozole and clomiphene citrate for ovulation induction. J Obstet Gynaecol Can. 2007;29:668-671.</Citation>
        </Reference>
        <Reference>
          <Citation>PCOS_Evidence-Based-Guidelines_20181009.pdf.</Citation>
        </Reference>
        <Reference>
          <Citation>Legro RS, Brzyski RG, Diamond MP, et al. Letrozole versus Clomiphene for Infertility in the polycystic ovary syndrome. N Engl J Med. 2014;371:119-129.</Citation>
        </Reference>
        <Reference>
          <Citation>Liu C, Feng G, Huang W, et al. Comparison of clomiphene citrate and letrozole for ovulation induction in women with polycystic ovary syndrome: A prospective randomized trial. Gynecol Endocrinol. 2017;33:872-876.</Citation>
        </Reference>
        <Reference>
          <Citation>Kar S. Current evidence supporting “letrozole” for ovulation induction. J Hum Reprod Sci. 2013;6:93.</Citation>
        </Reference>
        <Reference>
          <Citation>Seyedoshohadaei F. Comparison of the effect of Clomiphene- estradiol valerate vs letrozole on endometrial thickness, abortion and pregnancy rate in infertile women with polycystic ovarian syndrome. J Clin Diagn Res. 2016;10:QC10-QC13.</Citation>
        </Reference>
        <Reference>
          <Citation>Banerjee Ray P, Ray A, Chakraborti PS. Comparison of efficacy of letrozole and clomiphene citrate in ovulation induction in Indian women with polycystic ovarian syndrome. Arch Gynecol Obstet. 2012;285:873-877.</Citation>
        </Reference>
        <Reference>
          <Citation>Franik S, Eltrop SM, Kremer JA, Kiesel L, Farquhar C. Aromatase inhibitors (letrozole) for subfertile women with polycystic ovary syndrome. Cochrane Database Syst Rev. 2018;(5):CD010287. https://doi.org/10.1002/14651858.pub3.</Citation>
        </Reference>
        <Reference>
          <Citation>Wang R, Li W, Bordewijk EM, et al. First-line ovulation induction for polycystic ovary syndrome: An individual participant data meta-analysis. Hum Reprod Update. 2019;25:717-732.</Citation>
        </Reference>
        <Reference>
          <Citation>Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19:41-47.</Citation>
        </Reference>
        <Reference>
          <Citation>Akbari S. Comparing of letrozole versus clomiphene citrate combined with gonadotropins in intrauterine insemination cycles. Iran J Reprod Med. 2012;10:29.</Citation>
        </Reference>
        <Reference>
          <Citation>Xue X, Liu S, Yang Y, Lu X, Xi W, Mao H. Use of letrozole and clomiphene citrate combined with gonadotropins in clomiphene-resistant infertile women with polycystic ovary syndrome: A prospective study. Drug Design, Development and Therapy. 2015;9:6001.</Citation>
        </Reference>
        <Reference>
          <Citation>Chakravorty R, Athwal A, Sur D, Saha R. A prospective, randomized trial comparing the effects of letrozole versus clomiphene citrate for induction of ovulation and pregnancy rate in women with polycystic ovary syndrome. Fertil Sci Res. 2016;3:93.</Citation>
        </Reference>
        <Reference>
          <Citation>Ellakwa HE, Sanad ZF, Hamza HA, Emara MA, Elsayed MA. Predictors of patient responses to ovulation induction with clomiphene citrate in patients with polycystic ovary syndrome experiencing infertility. Int J Gynecol Obstet. 2016;133:59-63.</Citation>
        </Reference>
        <Reference>
          <Citation>McKnight KK, Nodler JL, Cooper JJ, Chapman VR, Cliver SP, Bates GW. Body mass index-associated differences in response to ovulation induction with letrozole. Fertil Steril. 2011;96:1206-1208.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
